Are You At Risk For Dementia?
Are You At Risk For Dementia?
A combination of two enzymes, recommended for circulatory health, might become a preventive supplement against Alzheimer’s disease—this at a time when the aging baby boomer population is predicted to make the future number of memory loss cases an epidemic with enormous economic and human consequences.
Serrapeptase (SP) and Nattokinase (NK) are proteolytic enzymes used for pain relief and blood flow, respectively, as substitutes for some medications that might otherwise have toxic side effects. The researchers hypothesized SP and NK could mediate factors associated with Alzheimer’s disease (AD) pathology.
One of the symptoms of the brain under siege is hyperactivity caused by its overcompensation for the low level chronic damage. By using aluminum chloride, the study induced AD-like pathology in an experimental model “with a significant increase in brain acetylcholinesterase (AchE) activity, transforming growth factor β (TGF-β), Fas and interleukin-6 (IL-6) levels.”
Meanwhile, significant decreases in brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1) ensued.
Also, a decline in the expression levels of disintegrin and metalloproteinase domain 9 (ADAM9), two enzymes linked with brain health, were accompanied by reduced expression of the disintegrin and metalloproteinase domain 10 (ADAM10) genes in the brain. All of this downside was countered with the supplements.
Oral administration of SP or NK for 45 days resulted in a significant decrease in brain AchE activity, TGF-β, Fas cell receptors and IL-6 levels. This indicates much less damage to the brain. Also, the treatment with these enzymes produced significant increases in BDNF and IGF-1 levels. But most interestingly, SP and NK increased the expression levels of ADAM9 and ADAM10 genes in brain tissue. “These findings were well confirmed” and “support our hypothesis that the oral administration of proteolytic enzymes, SP and/ or NK, would have an effective role in modulating certain factors characterizing AD. Thus, these enzymes may have a therapeutic application in the treatment of AD.”
By 2025, the number of people 65 and older with Alzheimer’s disease is estimated to reach 7.1 million—a 40% increase from the 5.1 million aged 65 and older affected in 2015, says the Alzheimer’s Association. “By 2050, the number of people age 65 and older with Alzheimer’s disease may nearly triple, from 5.1 million to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease.”
shopping for supplement
Besides serrapeptase and nattokinase, an Alzheimer’s disease prevention supplement might also supply proteases, lipase, bromelain, papain, rutin, amla and coenzyme Q10. Bromelain, papain and proteases digest proteins. Lipase breaks apart fat. Rutin and amla, sources of flavonoids, synergize systemic enzymes. Coenzyme Q10 stokes metabolism by feeding the cellular energy factories called mitochondria. These supplements are overall anti-inflammatory in their effect and can be used simultaneously for lowering levels of inflammation markers such as C-reactive protein.ReferenceFadl NN, Ahmed HH, Booles HF, Sayed AH. Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum Exp Toxicol. 2013 July;32(7):721-735. doi: 10.1177/096032711246704